NASDAQ · STAA
Healthcare · Medical - Instruments & Supplies
$22.38
Down-$0.23 (-1.02%)
Updated Oct 2, 2026, 4:27 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · STAA
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 1, 2026
STAA closed at $22.38 after 20 trading sessions, down 5.07% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 1, 2026 | $22.63 | $22.97 | $22.01 | $22.38 | 776.26K |
| Sep 30, 2026 | $22.48 | $22.75 | $22.05 | $22.61 | 798.87K |
| Sep 29, 2026 | $22.20 | $22.92 | $21.95 | $22.43 | 1.66M |
| Sep 28, 2026 | $20.43 | $20.96 | $20.16 | $20.87 | 540.76K |
| Sep 25, 2026 | $19.91 | $20.80 | $19.70 | $20.51 | 1.31M |
| Sep 24, 2026 | $19.80 | $20.08 | $19.05 | $19.08 | 880.09K |
| Sep 23, 2026 | $20.66 | $21.00 | $19.65 | $19.80 | 846.69K |
| Sep 22, 2026 | $20.40 | $21.03 | $20.14 | $20.65 | 751.16K |
| Sep 21, 2026 | $21.00 | $21.03 | $20.18 | $20.32 | 768.56K |
| Sep 18, 2026 | $21.11 | $21.155 | $20.47 | $20.82 | 5.74M |
| Sep 17, 2026 | $22.46 | $22.555 | $21.165 | $21.24 | 786.72K |
| Sep 16, 2026 | $22.62 | $22.97 | $22.29 | $22.41 | 711.15K |
| Sep 15, 2026 | $23.03 | $23.03 | $22.21 | $22.445 | 1.08M |
| Sep 14, 2026 | $22.75 | $23.155 | $22.215 | $23.07 | 798.07K |
| Sep 11, 2026 | $23.73 | $23.78 | $22.10 | $22.66 | 838.69K |
| Sep 10, 2026 | $23.36 | $23.741 | $23.02 | $23.42 | 680.98K |
| Sep 9, 2026 | $23.90 | $24.265 | $23.37 | $23.62 | 827.85K |
| Sep 8, 2026 | $23.14 | $24.355 | $22.66 | $24.16 | 1.4M |
| Sep 4, 2026 | $23.47 | $24.365 | $23.40 | $23.47 | 1.97M |
| Sep 3, 2026 | $23.15 | $23.68 | $22.71 | $23.575 | 798.35K |
The latest Smart Investors Daily articles mentioning STAA.
Company
Market Activity
Research & News
STAA research
Company profile and research snapshot.
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 29, 2026 | Stifel | Buy | — |
| Sep 22, 2026 | Jefferies | Buy | — |
| Aug 17, 2026 | Stifel | Hold | — |
| Aug 13, 2026 | UBS | Sell | — |
| Aug 13, 2026 | Wedbush | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 29, 2026
Shares of medical lens company STAAR Surgical (NASDAQ:STAA) jumped 6.4% in the pre-market session after Stifel upgraded the company from Hold to Buy and lifted its price target to $31.00 from $28.00, StreetInsider reported.
Yahoo · Sep 29, 2026
Investing.com -- STAAR Surgical Company (NASDAQ:STAA) shares rallied 7% in early Tuesday trade following an upgrade from Stifel, which pointed to improving international sales momentum and favorable product mix trends. Analyst Thomas Stephan raised Stifel's rating on the ophthalmic medical device manufacturer to Buy from Hold while lifting its price target to $31 from $28.
Benzinga · Sep 29, 2026
Stifel analyst Thomas Stephan upgrades Staar Surgical (NASDAQ:STAA) from Hold to Buy and raises the price target from $28 to $31.
Yahoo · Sep 25, 2026
It has launched a $50 million share repurchase program.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning STAA.
